FDA Two new Q&As published for Investigational Drugs
Register now for ECA's GMP Newsletter
The U.S. Food and Drug Administration FDA has published two new Question and Answer Documents on Investigational Drugs.
One of the draft Guidance for Industry documents is intended to provide information for industry, researchers, and physicians about the implementation of FDA's regulation on charging for investigational drugs under an Investigational New Drug Application (IND) (21 CFR 312.8). The other one is intended to provide information about the implementation of FDA's regulations on expanded access to investigational drugs for treatment use under an investigational new drug application (IND) (21 CFR part 312, subpart I).
Both documents are being distributed for comment purposes only.
Related GMP News
25/11/2020
GMP Conferences by Topics
- General Quality Assurance and GMP Compliance Topics
- Hygiene
- General Microbiology Topics
- Regulatory Affairs
- Development
- General Analytics Topics
- Good Distribution Practice
- Sterile Manufacturing
- Computer Validation
- General Qualification/Validation Topics
- General Engineering Topics
- APIs/Excipients
- GMP Basic Training Courses
- Medical Devices and Combination Products
- Packaging and Packaging Material
- Data Integrity
- Qualified Person (QP)
- GMP Auditing
- Documentation
- Cleaning Validation
- General IT Compliance Topics
- Impurities
- OOS / OOE / OOT
- Material Testing
- Validation of Analytical Methods
- Analytical Instrument Qualification
- Stability Testing
- Microbiological Testing
- Technology
- General Manufacturing Topics
- Solid Dosage Forms/Semi-Solid Dosage Forms
- Biotechnology/Blood/ATMP
- Herbal Drug Products/Cannabis/Radiopharmaceuticals
- Others